Patents by Inventor Tadakiyo Nakagawa
Tadakiyo Nakagawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9655879Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: GrantFiled: November 6, 2015Date of Patent: May 23, 2017Assignee: EA Pharma Co., Ltd.Inventors: Takahiro Koshiba, Munetaka Tokumasu, Taisuke Ichimaru, Koji Ohsumi, Tadakiyo Nakagawa, Tatsuhiro Yamada, Kayo Matsumoto, Tamotsu Suzuki
-
Publication number: 20160137633Abstract: Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Ar2 is represented by any one of the following rings and the like.Type: ApplicationFiled: January 29, 2016Publication date: May 19, 2016Applicant: Ajinomoto Co., Inc.Inventors: Tadakiyo NAKAGAWA, Kayo Matsumoto, Sen Takeshita, Tomomi Yoshida, Munetaka Tokumasu, Hiroki Inoue, Kaori Kobayashi
-
Patent number: 9290487Abstract: Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Ar2 is represented by any one of the following rings and the like.Type: GrantFiled: May 2, 2014Date of Patent: March 22, 2016Assignee: AJINOMOTO CO., INC.Inventors: Tadakiyo Nakagawa, Kayo Matsumoto, Sen Takeshita, Tomomi Yoshida, Munetaka Tokumasu, Hiroki Inoue, Kaori Kobayashi
-
Publication number: 20160058734Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: ApplicationFiled: November 6, 2015Publication date: March 3, 2016Applicant: AJINOMOTO CO., INC.Inventors: Takahiro KOSHIBA, Munetaka Tokumasu, Taisuke Ichimaru, Koji Ohsumi, Tadakiyo Nakagawa, Tatsuhiro Yamada, Kayo Matsumoto, Tamotsu Suzuki
-
Publication number: 20160046592Abstract: An object is to provide a novel compound which has a glycogen synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe.Type: ApplicationFiled: October 30, 2015Publication date: February 18, 2016Applicant: Ajinomoto Co., Inc.Inventors: Kayo MATSUMOTO, Wataru MIYANAGA, Mizuki DOHI, Tadakiyo NAKAGAWA, Kaori KOBAYASHI, Sen TAKESHITA
-
Patent number: 9227949Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: GrantFiled: December 11, 2014Date of Patent: January 5, 2016Assignee: AJINOMOTO CO., INC.Inventors: Takahiro Koshiba, Munetaka Tokumasu, Taisuke Ichimaru, Koji Ohsumi, Tadakiyo Nakagawa, Tatsuhiro Yamada, Kayo Matsumoto, Tamotsu Suzuki
-
Patent number: 9024044Abstract: Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: GrantFiled: June 14, 2012Date of Patent: May 5, 2015Assignee: Ajinomoto Co., Inc.Inventors: Takahiro Koshiba, Munetaka Tokumasu, Taisuke Ichimaru, Koji Ohsumi, Tadakiyo Nakagawa, Tatsuhiro Yamada, Kayo Matsumoto, Tamotsu Suzuki
-
Publication number: 20150099733Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: ApplicationFiled: December 11, 2014Publication date: April 9, 2015Applicant: AJINOMOTO CO., INC.Inventors: Takahiro KOSHIBA, Munetaka TOKUMASU, Taisuke ICHIMARU, Koji OHSUMI, Tadakiyo NAKAGAWA, Tatsuhiro YAMADA, Kayo MATSUMOTO, Tamotsu SUZUKI
-
Publication number: 20140336376Abstract: Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe. In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Ar2 is represented by any one of the following rings and the like.Type: ApplicationFiled: May 2, 2014Publication date: November 13, 2014Applicant: Ajinomoto Co., Inc.Inventors: Tadakiyo NAKAGAWA, Kayo Matsumoto, Sen Takeshita, Tomomi Yoshida, Munetaka Tokumasu, Hiroki Inoue, Kaori Kobayashi
-
Publication number: 20130338132Abstract: Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: ApplicationFiled: June 14, 2012Publication date: December 19, 2013Applicant: Ajinomoto Co., Inc.Inventors: Takahiro Koshiba, Munetaka Tokumasu, Taisuke Ichimaru, Koji Ohsumi, Tadakiyo Nakagawa, Tatsuhiro Yamada, Kayo Matsumoto, Tamotsu Suzuki
-
Patent number: 8309561Abstract: Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.Type: GrantFiled: December 21, 2007Date of Patent: November 13, 2012Assignee: Ajinomoto Co., Inc.Inventors: Kazuyuki Sagi, Tatsuya Okuzumi, Tatsuhiro Yamada, Shunsuke Kageyama, Yoichiro Shima, Tadakiyo Nakagawa, Munetaka Tokumasu, Masayuki Sugiki, Hajime Ito, Itsuya Tanabe, Tamotsu Suzuki, Akira Nakayama, Kazuyuki Ubukata, Kenji Shinkai, Yasuhiro Tanaka, Misato Noguchi, Ayatoshi Andou, Yoriko Yamamoto, Noriyasu Kataoka, Koichi Fujita
-
Patent number: 8168827Abstract: Amide derivatives represented by the formula (I): wherein: A is a cycloalkyl group, an aryl group or a heteroaryl group; X is a nitrogen atom or CR17; Y is —NRa-, —(CRbRb?)m-, and the like; m is 0 to 4; and R1 to R17 may be the same or different and each is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a hydroxyl group, an ammonium group, an alkyl group optionally having one or more substituents, -ZR18 and the like, Z is —O—, —S(O)p-, —S(O)pO—, —NH—, —NR19-, and the like; or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof may be applied to pharmaceutical use such as anti-inflammatory and analgesic action and the like.Type: GrantFiled: June 19, 2009Date of Patent: May 1, 2012Assignee: Ajinomoto Co., Inc.Inventors: Tadakiyo Nakagawa, Tamotsu Suzuki, Kaoru Takenaka, Shinichi Fujita, Youji Yamada, Yoichiro Shima, Tatsuya Okuzumi, Toshihiko Yoshimura, Masanao Yoshida, Masahiro Murata
-
Publication number: 20120088737Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 12, 2012Applicant: AJINOMOTO CO., INCInventors: Wataru MIYANAGA, Yoichiro SHIMA, Misato NOGUCHI, Akiko OONUKI, Yayoi KAWATO, Hiroshi IWATA, Eri HARADA, Ryuta TAKASHITA, Hirokazu UENO, Tadakiyo NAKAGAWA
-
Publication number: 20110082109Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: AJINOMOTO CO., INC.Inventors: Wataru MIYANAGA, Yoichiro Shima, Misato Noguchi, Akiko Oonuki, Yayoi Kawato, Hiroshi Iwata, Eri Harada, Ryuta Takashita, Hirokazu Ueno, Tadakiyo Nakagawa
-
Patent number: 7902179Abstract: A pharmaceutical composition containing a heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-? production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-?.Type: GrantFiled: April 26, 2002Date of Patent: March 8, 2011Assignee: Ajinomoto Co., Inc.Inventors: Yasuhiro Tanaka, Kohichi Fujita, Yoshitomo Chujoh, Syunsuke Fukuda, Yuka Ikenoue, Tomoyuki Tagami, Akira Chiba, Ariko Kodaira, Hideki Matsumoto, Tadakiyo Nakagawa, Tatsuhiro Yamada, Manabu Suzuki, Masahiro Murata
-
Patent number: 7728005Abstract: The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.Type: GrantFiled: April 13, 2006Date of Patent: June 1, 2010Assignee: Ajinomoto Co., Inc.Inventors: Tatsuya Okuzumi, Tamotsu Suzuki, Youji Yamada, Shinichi Fujita, Yoichiro Shima, Yoriko Yamamoto, Tetsuo Yano, Tadakiyo Nakagawa
-
Publication number: 20100093973Abstract: Herein disclosed is a water-soluble compound represented by the following general formula (I) or a salt thereof. The compound is a novel water-soluble compound having an inhibitory effect on the absorption of phosphorus in vivo. where the structural variables are defined herein.Type: ApplicationFiled: August 27, 2009Publication date: April 15, 2010Applicant: AJINOMOTO CO., INC.Inventors: Tadakiyo Nakagawa, Hironobu Tsugeno, Naomi Matsutani, Masayuki Sugiki, Haruko Hirashima, Tatsuya Okuzumi, Tatsuya Kasahara, Wataru Miyanaga, Takashi Yamamoto, Masatsugu Noguchi, Kayo Matsumoto, Hideyuki Tanaka, Tomoyuki Konda
-
Publication number: 20090258900Abstract: Amide derivatives represented by the formula (I): wherein: A is a cycloalkyl group, an aryl group or a heteroaryl group; X is a nitrogen atom or CR17; Y is —NRa—, —(CRbRb?)m-, and the like; m is 0 to 4; and R1 to R17 may be the same or different and each is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a hydroxyl group, an ammonium group, an alkyl group optionally having one or more substituents, -ZR18 and the like, Z is —O—, —S(O)p-, —S(O)pO—, —NH—, —NR19-, and the like; or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof may be applied to pharmaceutical use such as anti-inflammatory and analgesic action and the like.Type: ApplicationFiled: June 19, 2009Publication date: October 15, 2009Applicant: AJINOMOTO CO. INCInventors: Tadakiyo Nakagawa, Tamotsu Suzuki, Kaoru Takenaka, Shinichi Fujita, Youji Yamada, Yoichiro Shima, Tatsuya Okuzumi, Toshihiko Yoshimura, Masanao Yoshida, Masahiro Murata
-
Patent number: 7572815Abstract: Amide derivatives represented by the formula (I): wherein: A is a cycloalkyl group, an aryl group or a heteroaryl group; X is a nitrogen atom or CR17; Y is —NRa—, —(CRbRb?)m-, and the like; m is 0 to 4; and R1 to R17 may be the same or different and each is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a hydroxyl group, an ammonium group, an alkyl group optionally having one or more substituents, ZR18 and the like, Z is —O—, —S(O)p-, —S(O)pO—, —NH—, —NR19-, and the like; or R1 and R2 may in combination form a ring, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof may be applied to pharmaceutical use such as anti-inflammatory and analgesic action and the like.Type: GrantFiled: November 18, 2005Date of Patent: August 11, 2009Assignee: Ajinomoto Co., Inc.Inventors: Tadakiyo Nakagawa, Tamotsu Suzuki, Kaoru Takenaka, Shinichi Fujita, Youji Yamada, Yoichiro Shima, Tatsuya Okuzumi, Toshihiko Yoshimura, Masanao Yoshida, Masahiro Murata
-
Patent number: 7396844Abstract: Benzamidine derivatives of the following formulae or analogs thereof, i.e., pharmaceutically acceptable salts thereof, are provided.Type: GrantFiled: July 19, 1999Date of Patent: July 8, 2008Assignee: Ajinomoto Co., Inc.Inventors: Masaru Takayanagi, Kazuyuki Sagi, Tadakiyo Nakagawa, Masahiro Yamanashi, Takashi Kayahara, Shunji Takehana, Yumiko Fukuda, Mitsuo Takahashi, Masataka Shoji